Background:Background: Pulmonary arterial hypertension (PAH) is considered an orphan disease. Prostacyclins are the keystone for PAH treatment. Choosing between the three available prostacyclin therapies could be complicated because there are no comparison studies, so the final decision must be...

Background:Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially fatal disease. Little is known about the economic burden associated with CTEPH patients in the US. Abstract: Objectives:Objectives: The objective of this study was to estimate excess direct...

Background: Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Little is known about the economic burden associated with PAH patients in the US. Objectives: The objective of this study was to estimate excess direct costs associated with privately insured PAH patients in the US....